Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 6/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | DRD1 | P21728 | 1/20 | 0.42 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5514265 | 0.93 | CYP2D6 (0.41) | CYP2D6CYP3A4ALOX15SCN9AOPRM1 | |
| SCHEMBL24238344 | 0.92 | OPRM1 (0.42) | CYP2D6CYP3A4ALOX15SCN9AOPRM1 | |
| SCHEMBL24238281 | 0.92 | OPRM1 (0.42) | CYP2D6CYP3A4ALOX15SCN9AOPRM1 | |
| SCHEMBL24238345 | 0.92 | CYP2D6 (0.40) | CYP2D6CYP3A4ALOX15SCN9AOPRM1 | |
| Maleic Acid SCHEMBL6971291 | 0.90 | ALDH1A1 (0.49) | CYP2D6CYP3A4ALOX15SCN9ATSHR | |
| Fumaric Acid SCHEMBL6971299 | 0.90 | ALDH1A1 (0.49) | CYP2D6CYP3A4ALOX15SCN9ATSHR | |
| SCHEMBL2265275 | 0.88 | CYP2D6 (0.45) | CYP2D6CYP3A4ALOX15SCN9AOPRM1 | |
| SCHEMBL2264060 | 0.88 | CYP2D6 (0.45) | CYP2D6CYP3A4ALOX15SCN9AOPRM1 | |
| SCHEMBL9684294 | 0.86 | CYP2D6 (0.49) | CYP2D6OPRM1CHRM2CHRM4CHRM5 | |
| SCHEMBL5745189 | 0.86 | CYP2D6 (0.44) | CYP2D6CYP3A4ALOX15SCN9AOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 825 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4943641-A | 3-aminoazetidine, its salts, process for their preparation and intermediates of synthesis | SANOFI (FR) | 1990-07-24 | — | — | US | claimed |
| EP-0155870-B1 | 3-AMINOAZETIDINE, ITS SALTS, PROCESS FOR THEIR PREPARATION AND INTERMEDIATES | SANOFI (FR) | 1989-04-26 | — | — | EP | claimed |
| EP-0155870-A1 | 3-Aminoazetidine, its salts, process for their preparation and intermediates | SANOFI (FR) | 1985-09-25 | — | — | EP | claimed |
| EP-3364967-B1 | FERROPORTIN INHIBITORS | VIFOR INT AG (CH) | 2026-05-20 | — | — | EP | disclosed |
| US-20260042759-A1 | INHIBITOR CONTAINING BICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO LTD (CN) | 2026-02-12 | — | — | US | disclosed |
| US-20260021095-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEASOME PATHWAY | NIKANG THERAPEUTICS INC (US) | 2026-01-22 | — | — | US | disclosed |
| US-20250367193-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING SUBSTITUTED PYRIMIDINE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEASOME PATHWAY | NIKANG THERAPEUTICS INC (DE) | 2025-12-04 | — | — | US | disclosed |
| WO-2025235261-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING 2,4,5-SUBSTITUTED PYRIMIDINE DERIVATIVES FOR DEGRADING CERTAIN CYCLIN-DEPENDENT KINASE VIA UBIQUITIN PROTEASOME PATHWAY | NIKANG THERAPEUTICS, INC. (US) | 2025-11-13 | — | — | WO | disclosed |
| WO-2025235331-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING PYRAZOLOPYRIMIDINE DERIVATIVES FOR DEGRADING CERTAIN CYCLIN-DEPENDENT KINASE VIA UBIQUITIN PROTEASOME PATHWAY | NIKANG THERAPEUTICS, INC. (US) | 2025-11-13 | — | — | WO | disclosed |
| WO-2025235298-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING THIAZOLYL DERIVATIVES FOR DEGRADING CERTAIN CYCLIN-DEPENDENT KINASE VIA UBIQUITIN PROTEASOME PATHWAY | NIKANG THERAPEUTICS, INC. (US) | 2025-11-13 | — | — | WO | disclosed |
| US-12466823-B2 | Inhibitor containing bicyclic derivative, preparation method therefor and use thereof | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2025-11-11 | — | — | US | disclosed |
| US-4594189-A | Process for preparing 3-phenoxy-1-azetidines and carboxamide derivatives | A. H. ROBINS COMPANY, INC. (US) | 1986-06-10 | — | — | US | disclosed |
| US-4571393-A | ANTICONVULSANT TREATMENT FOR MAMMALS | A. H. ROBINS COMPANY, INCORPORATED (US) | 1986-02-18 | — | — | US | disclosed |
| EP-0155870-A1 | 3-Aminoazetidine, its salts, process for their preparation and intermediates | SANOFI (FR) | 1985-09-25 | — | — | EP | disclosed |
| US-4505907-A | ANTICONVULSANTS | A. H. ROBINS COMPANY, INC. (US) | 1985-03-19 | — | — | US | disclosed |
| EP-0131435-A1 | Process for preparing 3-phenoxy-1-azetidines and carboxamide derivatives | A.H. ROBINS COMPANY, INCORPORATED (US) | 1985-01-16 | — | — | EP | disclosed |
| EP-0102740-A1 | N-formyl and n-hydroxymethyl-3-phenoxy-1-azetidinecarboxamides and their preparation and use | A.H. ROBINS COMPANY, INCORPORATED (US) | 1984-03-14 | — | — | EP | disclosed |
| EP-0102194-A1 | 3-Phenoxy-1-azetidinecarboxamides and their use and preparation | A.H. ROBINS COMPANY, INCORPORATED (US) | 1984-03-07 | — | — | EP | disclosed |
| US-4379151-A | 3-Phenoxyazetidines for anorexigenic activity | A. H. ROBINS COMPANY, INC. (US) | 1983-04-05 | — | — | US | disclosed |
| US-4183923-A | 3-ALKANESULFONYLOXYAZETIDINES | SCHERING CORPORATION (US) | 1980-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260021095-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEASOME PATHWAY | PSMB2, PSMB7, MDM2 | CYP2D6 2264/4885CYP3A4 2789/4885ALOX15 3772/4885 |
| US-20260042759-A1 | INHIBITOR CONTAINING BICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | FAR1, CYP4A11, CYP11B1 | CYP2D6 724/4885CYP3A4 392/4885ALOX15 416/4885 |
| US-20250367193-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING SUBSTITUTED PYRIMIDINE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEASOME PATHWAY | CDK2, SKP2, CCNK | CYP2D6 3160/4885CYP3A4 3662/4885ALOX15 4281/4885 |
| US-12466823-B2 | Inhibitor containing bicyclic derivative, preparation method therefor and use thereof | RET, REL, GOT1 | CYP2D6 746/4885CYP3A4 101/4885ALOX15 271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.